Bliss Kelly sold $22K of TDOC
Bliss Kelly (President, U.S. Group Health) sold 2,500 shares of Teladoc Health, Inc. (TDOC) at $9.00 on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale (2,500 shares at $9.00) by Bliss Kelly, President of the U.S. Group Health segment, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the disclosed insider selling, but the 10b5-1 framing suggests limited incremental information for TDOC’s near-term valuation.
What to watch
The article provides only the sale size/price and post-transaction holdings; it does not indicate whether other insiders bought/sold, nor whether the plan was modified or accelerated.
Background
This is an SEC Form 4 insider transaction disclosure for Teladoc Health, Inc. (TDOC).
Ticker impact
Teladoc Health insider Bliss Kelly sold 2,500 shares on 2026-07-01 at $9.00/share under a pre-arranged 10b5-1 plan.
Low near-term impact; any effect is likely muted and short-lived.
The filing is a disclosed open-market sale with a stated 10b5-1 plan, which typically reduces interpretive weight for directional information.
Market effects
No clear sector read-through; this is an individual insider transaction.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal risk management or diversification, which some traders may still monitor.
Key entities
- issuerTeladoc Health, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderBliss Kelly
President, U.S. Group Health; reported open-market sale of 2,500 shares.
- trading mechanism10b5-1 plan
Pre-arranged plan cited as Yes, which typically reduces interpretive signal.
